

Fresenius Annual General Meeting

Frankfurt am Main, May 17, 2024
Presentation of Michael Sen, CEO of the Management Board

Fresenius



Every fourth blood bag worldwide comes from Fresenius

27 million

blood bags sold in 2023



#FutureFresenius



#FutureFresenius Four phases to becoming the leading healthcare company

REVITALIZE

REIMAGINE

REJUVENATE




#FutureFresenius Four phases to becoming the leading healthcare company

REIMAGINE

REJUVENATE



Share price: continuous improvement since turnaround






Raised outlook for 2024 fiscal year

3-6% 4-7% Organic revenue growth

4-8%
6-10%
EBIT growth
before special items
in constant currency



Historic step through deconsolidation For greater freedom and responsibility



Simplified structure, sharper focus



2023 fiscal year a success

Fresen	IIIC
LI CSCII	

Revenue	€22.3bn	+6 %*
EBIT	€2.3bn	+2 %**
EBIT margin	10.1 %	
Operating cash flow	€2.1bn	+5%

^{*} Organic growth
** EBIT growth rate in constant currency

Consistently good performance Fresenius Kabi and Fresenius Helios

		Q1 23	Q2 23	Q3 23	FY 23
Fresenius Kabi	Revenue* EBIT	+7 %** ✓ -4 % ✓	+7 %** +1 %	+7 %** +2 %	+7 %** • +3 % •
Fresenius Helios	Revenue* EBIT	+5 % ~ +2 % ~	+6 % ~ +3 % ~	+6 % ~ +4 % ~	+5 % ~ +4 % ~

Before special items; EBIT growth rates in constant currency

^{*} Organic growth

^{**} Excluding the significant inflationary effects in Argentina

Growth on a broad basis 2023 fiscal year at Fresenius Kabi

Fresenius Kabi

Revenue*	€8bn	+7 % Ambition level: 4-7%)
€1.15bn		+3 %***	
EBIT margin	14.3 %	Ambition level: 14 - 17	′ %

^{*} Organic growth

^{**} Excluding the significant inflationary effects in Argentina

^{***} EBIT growth rates in constant currency

Digitalization paying off 2023 fiscal year at Fresenius Helios


Fresenius Helios

Revenue*	€12.3bn	+5 % Ambition level: 3 - 5 %	
EBIT	€1.2bn	+4 %**	
EBIT margin	10.0 %	Ambition level: 9 - 11 %	

^{*} Organic growth

^{**} EBIT growth rates in constant currency

On track to achieve ambitious savings targets Cost and efficiency program leading to greater competitiveness





Fresenius Kabi



Fresenius Kabi



Innovative **development** and production platform.

Strong network for biopharmaceuticals.



Fresenius Kabi

Biopharma

Cost-efficient and highly effective alternatives for treating cancer and autoimmune diseases.

Excellent start with biosimilar Tyenne® in USA and EU.



Fresenius Helios



Fresenius Helios



Modern technologies in daily clinical practice for optimized patient care.

20 DaVinci surgical robots in use at Helios hospitals in Germany.




Fresenius Helios



Casiopea digital healthcare platform simplifies clinical processes.

6 million active users in Spain (approx. 12.5% of population).





Robust and dynamic growth The global market for healthcare services






Source: Projections for the International Healthcare Sector, 2023 (The Business Research Company)

Driver of the healthcare industry: technology



Artificial intelligence in healthcare Market size in US dollars



Source: Artificial Intelligence (AI) in Healthcare Market Size Worldwide from 2021 to 2030 (Statista)



Driver of the healthcare industry: data




Digitalization of healthcare

"Digitizing the patient healthcare journey offers a wide range of benefits and solutions to healthcare system challenges by **enhancing efficiency**, **improving patient outcomes**, and **increasing access to healthcare**."

World Economic Forum, Transforming Healthcare 2024 Report



Driver of the healthcare industry: biomedical research



Focus on people



3 platforms for profitable growth




Market potential of the 3 platforms

€1 trillion



The Fresenius ecosystem A strong global network

F Fresenius



Team Fresenius is growing

+5,000 employees in 2023


6,700 apprentices and dual students

40 apprenticeships

30 dual study programs



ESG influences our actions On course for climate neutrality







A leading global company

80 countries190,000+ colleagues150 nationalities



Active for our patients worldwide





COMMITED TO LIFE